Equities

Atossa Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Atossa Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.85
  • Today's Change-0.14 / -2.81%
  • Shares traded149.59k
  • 1 Year change-60.57%
  • Beta1.3751
Data delayed at least 15 minutes, as of Feb 10 2026 20:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

  • Revenue in USD (TTM)0.00
  • Net income in USD-30.18m
  • Incorporated2009
  • Employees13.00
  • Location
    Atossa Therapeutics Inc1448 NW MARKET STREET, SUITE 500SEATTLE 98107United StatesUSA
  • Phone+1 (206) 588-0256
  • Fax+1 (302) 636-5454
  • Websitehttps://atossatherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jasper Therapeutics Inc0.00-91.02m38.06m64.00--3.29-----5.90-5.900.000.41350.00----0.00-116.04-75.11-147.54-86.11------------0.00-------10.55------
Galecto Inc0.00-15.84m38.28m5.00--4.78-----12.01-12.010.006.030.00----0.00-92.89-47.05-109.09-50.67------------0.00------44.10------
Veru Inc0.00-15.68m38.36m20.00--1.91-----1.07-1.550.001.250.00----0.00-34.75-47.51-44.42-59.79-------188.81----0.00------55.53---60.02--
Cypherpunk Technologies Inc0.00-50.81m38.53m52.00--10.46-----1.23-1.230.000.0650.00----0.00-132.94-79.03-196.76-93.29-------9,055.53----0.00------16.74------
Liminatus Pharma Inc0.00-2.27m39.24m-----------0.0872-0.08720.00-0.06080.00-------77.46-----------------12.30--------28.85------
Lisata Therapeutics Inc1.07m-18.24m40.13m26.00--2.29--37.51-2.13-2.130.12461.980.0357----41,153.85-60.85-44.77-71.25-49.07-----1,704.86-13,065.70----0.00------4.10------
INmune Bio Inc50.00k-49.89m40.94m22.00--1.61--818.83-2.14-2.140.00210.95460.0012--0.02582,272.73-115.83-45.54-153.59-52.16-----99,774.00-19,298.45---942.220.00---90.97---40.24------
Atossa Therapeutics Inc0.00-30.18m42.97m13.00--0.8631-----3.52-3.520.005.780.00----0.00-43.90-26.93-48.89-29.04------------0.00------15.25--20.02--
CEL-SCI Corp0.00-25.41m44.15m43.00--2.64-----7.81-7.810.001.990.00-------92.16-72.20-111.94-80.91--------2.20-38.200.3328------7.86---57.33--
Aligos Therapeutics Inc2.65m-86.46m44.49m70.00--0.6194--16.81-12.70-12.700.296411.670.0267----37,800.00-87.25-60.83-111.39-72.31-----3,267.65-1,462.14----0.002---74.60---49.65---45.83--
ABVC Biopharma Inc797.92k-4.12m44.64m16.00--3.47--55.94-0.2223-0.22230.04640.49850.0448--0.40849,870.00-24.89-105.17-42.73-217.000.246975.19-555.90-2,124.210.6241-13.710.0662--234.31-6.2037.05------
Kezar Life Sciences Inc0.00-61.71m45.04m55.00--0.5428-----8.44-8.440.0011.330.00----0.00-47.14-34.75-54.13-36.82-------5,003.10----0.0742---100.00--17.80---45.57--
OS Therapies Inc0.00-20.26m45.78m4.00--11.89-----0.9794-0.97940.000.14150.00----0.00-334.55---870.52-------------2,674.490.00-------37.51------
Plus Therapeutics Inc (USA)5.26m-20.58m46.81m21.00--6.61--8.90-1.71-1.710.0620.03840.41----250,381.00-160.45-80.94---211.40-----391.33-605.55---2.190.00--18.54-3.612.54--59.47--
UMeWorld Inc7.93k-1.32m47.06m1.00------5,934.66-0.0148-0.01480.00009-0.04770.1253--1.717,930.00-2,066.65-273.32-----285.62-768.98-16,497.98-13,102.00---2.36----136.17---15.02------
Impact Biomedical Inc25.00k-44.19m47.17m2.00------1,886.95-3.76-3.760.0021-0.96910.0008--3.3312,500.00-136.32-18.99-260.12-26.2952.00---176,952.00-78,189.580.0182-0.26821.63-------469.83------
Data as of Feb 10 2026. Currency figures normalised to Atossa Therapeutics Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.